Sleeping sickness in the Democratic Republic of the Congo

High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo

A retrospective chart review of 4,925 human African trypanosomiasis patients treated with melarsoprol in 2001-2003 in Equateur Nord Province of the Democratic Republic of Congo showed a treatment failure rate of 19.5%. This rate increased over the 3 years. Relapse rates were highest in the central part of the province.

The effectiveness of active population screening and treatment for sleeping sickness control in the Democratic Republic of Congo.

BACKGROUND The human African trypanosomiasis (HAT) control programme of the Democratic Republic of Congo (DRC) uses mass screening with the card agglutination test for trypanosomes (CATT). We looked at the contribution of CATT and improved parasitological confirmation to the effectiveness of screening and treatment. METHOD The effectiveness of the screening and treatment process is measured b...

Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo

BACKGROUND Human African trypanosomiasis (HAT), or sleeping sickness, is a fatal neglected tropical disease if left untreated. HAT primarily affects people living in rural sub-Saharan Africa, often in regions afflicted by violent conflict. Screening and treatment of HAT is complex and resource-intensive, and especially difficult in insecure, resource-constrained settings. The country with the h...

Democratic Republic of Congo

Programme outcome: The IFRC 2010 support strategy and plan for the Red Cross of the Democratic Republic of Congo (Red Cross of DRC) was based on the National Society’s (NS) 20092013 Strategic Development Plan and was designed to help the NS provide vulnerable communities with life-saving first aid, clean water and sanitation, health and hygiene promotion, HIV/AIDS support, sexual and gender bas...

Mortality in the Democratic Republic of Congo